Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
True, stock analysts don't work for free.
It's a licensing deal. That's Lexaria's business model. Nothing wrong with royalties. So far we have 12 companies now licensed to us. Imagine the money rolling in when we have 100 or 500!
All these deals one after another...it's just terrible lol
Bunka just got voted in with 97% of the votes at the AGM. I guess you were one of the 3%.
I bought LEXX shares because I believe the MC will eventually be worth many hundreds of millions and I haven't changed that belief. IMO The SP going down is merely a temporary setback to shake off weak hands. Hang on for more thrills and chills and hopefully profits! Eventually it won't matter if you bought LEXX for $2 pre-split.
What do you think about the new Japanese deal?
Amazing low price with risk virtually eliminated. Bunka is delivering as promised. Bit of a wait to be sure but the waiting is over!!! Only sheep get the wool pulled over their eyes!
Get your facts straight! The Market cap is currently 13M US https://www.google.com/finance/quote/LEXX:NASDAQ?sa=X&ved=2ahUKEwiNod7hipL4AhXGIzQIHTVnDzkQ3ecFegQIHhAg
Now with this Japanese Deal that seems very possible.
I suppose when Altria makes their big move that would be the final straw!
Rome wasn't built in an hour and a half lol
Worst case LEXX makes $5M US/yr from one deal ..and somehow this is bad. lol whatever.
Valcon Address shows impressively large bldg. https://www.google.com/maps/place/Industrivej+12,+3540+Lynge,+Denmark/@55.8305631,12.3043965,222a,35y,39.46t/data=!3m1!1e3!4m5!3m4!1s0x46524472bdfb03e5:0x3a9d604ac07fe5c5!8m2!3d55.8321866!4d12.3051294
Not the yellow bldg #10 but the red one #12 behind it!
More info on Valcon Medical's EU-GMP certification. These guys are for real. https://www.prnewswire.com/news-releases/valcon-medical-as-announces-receipt-of-eu-gmp-certification-and-start-of-commercial-production-for-pharmaceutical-grade-cannabis-concentrates-intermediary-products-and-medical-formulations-301317236.html
@chunkmuck That's just pure FUD
Good thing this deal is with reputable people!
Thanks Shawking. Pete Patterson sounds very knowledgeable. Very promising for Lexaria to get a foot in the door in the European market in it's infancy. Good interview on the video. Funny about the Kelowna connection too.
GMP Certified means hardly a garage based company!
Valcon Medical is a European contract manufacturing organization ("CMO"), specialized in the manufacturing of medical cannabis extracts for the European Union ("EU") and the UK. Valcon is GMP certified and licensed under the Danish medical cannabis program to manufacture cannabis products that require physician-patient consultation.
Cannadips Co-Founder Case Mandel recently posted that Cannadips has solved "The Sleep Problem" and that we should be looking out for a new product soon! Hopefully and probably likely to be using DehydraTECH. https://www.linkedin.com/feed/update/urn:li:activity:6935714152082522113/
Perhaps a reminder that IP can be bought from someone else if patents are already owned. LEXX started the company by puchasing the Vipova Tea Patents. https://www.lexariabioscience.com/news/lexaria-bioscience-acquires-100-ownership-poviva-tea-llc/
Perhaps Chris has his eye on some useful IP.
We could improve the Oral Nicotine Pouch, Zyn that Swedish Match makes. They are currently the biggest oral nicotine pouch seller in the world. Also, if Phillip Morris International acquired Swedish Match then they would be upping their competition against Altria in the US for oral nicotine. Whoever finds an edge to a better product could end up dominating the market with the pouches, not only in the US but around the world.
Our study this summer NIC-H22-1 will actually be comparing both Altria's "On" pouches and SM's "Zyn" pouches with and without DehydraTECH to entice the companies to move ahead with incorporating our tech.
https://ir.lexariabioscience.com/news-events/press-releases/detail/170/lexaria-provides-update-on-human-nicotine-study-nic-h22-1
https://www.ft.com/content/ef5aa545-f017-4dc1-8955-76b6e1a5ee8b
No, our tech is a process with substances that get mixed with their products to improve them. My point in linking this deal is to show that the popularity of Oral pouches is escalating and this is when better products become more important. I'm sure you didn't miss how Altria is now re-evaluating our tech as I'm sure they are always interested in making their products better. That's what smart businesses do!
The article is about much more than kmart. If you read past the first paragraph you'll see what I mean. Also, good luck trying to dictate what any CEO wants to pay themselves.
IMO Bunka's positive skills and achievements far outweigh any negative ones and I believe he's the best choice we've got to lead us to a huge success. Bunka built this company with John Docherty and the rest of their team from scratch and know this company better than any newcomer ever will. Here's a great article that illustrates why switching out a CEO is usually dooming the company to a complete failure and bankruptcy. Is that what you all want?
https://hbr.org/2002/12/holes-at-the-top-why-ceo-firings-backfire
Shorts needed to cover before the celebration can move ahead!
there you go... $4.10 at 10 min in to reg trading!
Buccal Nicotine Absorption Studies from animals to humans
Here's Chris' statements on Nicotine studies from the Letter to Shareholders from earlier this year:
"In November 2021 we issued study results that demonstrated yet another first for Lexaria: in an animal study we evidenced that DehydraTECH was effective in promoting superior nicotine drug delivery characteristics in sublingual/buccal (oral) tissue.
DehydraTECH was originally developed to promote more efficient delivery of fat-soluble drugs across the intestinal wall, so our findings demonstrating its effectiveness also in enhancing sublingual/buccal (oral) absorption greatly enhances the value proposition for our technology for the oral nicotine products sector. This nicotine study was noteworthy not just because we delivered much higher levels of nicotine, more quickly; but also because we made this breakthrough utilizing buccal tissues of the mouth, gums and throat instead of through our traditional delivery through the intestines.
This was yet another opportunity demonstrating the versatility of DehydraTECH to work effectively in different parts of the body and opens doors to drug delivery through products such as lozenges, sub-lingual tablets, and other forms of non-swallowed oral products.
Because of this important new discovery for DehydraTECH, we are launching a very similar study in humans expected to start soon. If we can demonstrate similar performance of nicotine absorption through the sublingual/buccal tissue in humans, we feel that DehydraTECH will have advanced another big step in the direction of commercial applicability".
Here's the link to the 36 person nicotine study just announced.
https://ir.lexariabioscience.com/news-events/press-releases/detail/170/lexaria-provides-update-on-human-nicotine-study-nic-h22-1
Here's the results from last year's successful animal study.
https://ir.lexariabioscience.com/news-events/press-releases/detail/153/lexaria-oral-nicotine-study-nic-a21-1-delivers-outstanding
Altria to evaluate nicotine absorption tech by LEXX
https://ir.lexariabioscience.com/news-events/press-releases/detail/169/lexaria-begins-new-nicotine-formulation-creation-and
Altria must know of the nicotine study NIC-H22-1 LEXX is doing comparing their product "On" to DehydraTech. LEXX says they are paying for this study as opposed to the newly announced samples LEXX is supplying to Altria which they will receive "a fee" for. If the samples are the same ones then it would follow that LEXX and Altria have been planning this together since at least the beginning of the year when the Nicotine Study NIC-H22-1 was first announced. Either way, these collaborations are very positive considering we've done business with Altria before. We obviously haven't burned our proverbial bridges just yet!
It definitely seems the move to the buccal absorption format is picking up steam. The results from the Nicotine test results last Oct and now a new patent for buccal absorption (so far in Australia only but US and EU coming soon) are huge signs this is the direction our nicotine tech is going.
"As reported on October 5, 2021, Lexaria demonstrated in animal study NIC-A21-1 that nicotine oral pouches using DehydraTECH technology were 10x to 20x faster in reaching peak delivery of nicotine to bloodstream than controls. Findings using a DehydraTECH nicotine benzoate formulation relative to a concentration-matched control from that study are shown in the figure above.
The oral nicotine pouch category is of intense interest to Lexaria and is one of the fastest growing segments of the nicotine industry due in part to its reduced risk health outcomes as noted by the Food and Drug Administration ("FDA"). This delivery method, in the white pouch format specifically, which avoids harmful lung outcomes experienced by smokers or vapers, involves absorption primarily through the buccal tissues of the mouth, of purified nicotine that has been separated from most other harmful compounds in the tobacco leaf. The global market for the oral nicotine pouch category was US$2.33 billion in 2020 and is growing at a rapid CAGR of 30.7% and is expected to reach $21.84 billion in 2027.
As reported on March 8, 2022, Lexaria recently received its first ever patent granted to use DehydraTECH to more efficiently deliver nicotine through buccal tissue absorption. Similar patent filings have been made in the USA and in the EU and Lexaria believes those potential patent awards could support significant competitive advantages in the nicotine white pouch category, as well as other oral nicotine product formats.
This is awesome news. It's too bad Bunka can't share more info re: this agreement but when companies are creating new products which are highly competitive, the company owning the product not the one with the licensed tech, has first rights to the announcement of said new products with tech included.
Can't wait for LEXX to get its first paying nicotine and/or pharma licensing deals. Time for the SP to move on out.
You're wrong now lol.
No one needs to be here. If you have criticism or accolades for Lexaria, just send them an email.
There's a constant flux of new investor's. i.e. According to this list of Lexaria's Institutional Holdings, Invenomic Capital management currently owns 359,113 shares.
https://www.nasdaq.com/market-activity/stocks/lexx/institutional-holdings
I imagine that as the hopefully good news on FDA phases 1 and 2 are announced for the CBD indications for NDI's that the new institutional investors action should heat up. I would have liked to see things happen faster just like anyone but the groups with the big bucks are the ones controlling the SP and obviously the move to Big Pharma is a longer road than making puny royalty deals with Mom and Pop shops.
As far as a company partnering up with Lexaria, this would be the worst time for that with the SP at ATL. Better to give a partner 10% of the company at 100M cap than 50% of the company at 20M cap.
Definitely feeling positive for the coming year.